Who Paid My Doc
Barry Nelson
Addiction Psychiatry Spring House, PA Medical Doctor
NPI 1548390347 CMS profile 25115
809 North Bethlehem Pike, Spring House, PA 19477
General payments
$1,810
Research payments
$0
Ownership & investment interest
$0
Through program year 2023, Barry Nelson of Spring House, PA is reported in the CMS Open Payments database as having received $1,810 across 52 general payments and $0 in research payments paid to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.
General payments for this record sit in the 82nd percentile of Addiction Psychiatry profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
4 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2023 | General | $194 | 23 | |
| 2022 | General | $199 | 24 | |
| 2021 | General | $60 | 2 | |
| 2019 | General | $1,357 | 3 |
Beside peers
- Barry Nelson
- Addiction Psychiatry median
- Middle half of Addiction Psychiatry
- National median
In program year 2025, general payments to Barry Nelson were reported at $0. Among 180 Addiction Psychiatry profiles paid that year, the median was $138 and the middle half received between $45 and $421.
Show as a table
| Year | Barry Nelson | Addiction Psychiatry median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $1,357 | $142 | $56–$476 | $163 |
| 2020 | $0 | $78 | $21–$210 | $114 |
| 2021 | $60 | $112 | $35–$458 | $132 |
| 2022 | $199 | $113 | $39–$343 | $149 |
| 2023 | $194 | $134 | $47–$429 | $160 |
| 2024 | $0 | $129 | $42–$349 | $164 |
| 2025 | $0 | $138 | $45–$421 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Prescribing to Medicare patients
Part D · data year 2024 · 22 drugsPart D claims
559
Drug cost
$38,332
Branded share of claims
19.7%
| Drug | Type | Relative to their largest | Claims | Drug cost |
|---|---|---|---|---|
| Rexulti Brexpiprazole | Brand | 13 | $18,459 | |
| Trintellix Vortioxetine Hydrobromide | Brand | 14 | $6,853 | |
| Clozapine | Generic | 13 | $1,954 | |
| Duloxetine Hcl | Generic | 30 | $1,294 | |
| Divalproex Sodium Er Divalproex Sodium | Brand | 15 | $1,211 | |
| Bupropion Xl Bupropion Hcl | Brand | 28 | $1,201 | |
| Vilazodone Hcl | Generic | 11 | $955 | |
| Olanzapine | Generic | 12 | $757 | |
| Venlafaxine Hcl Er Venlafaxine Hcl | Brand | 40 | $739 | |
| Quetiapine Fumarate | Generic | 37 | $672 |
The 10 drugs with the highest cost, of 22 counted.
Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 1,891 Part D prescribers listed as Neuropsychiatry; they describe a distribution and say nothing about conduct.
Records
52 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Other Addiction Psychiatry in Pennsylvania
Daniel Langleben
Addiction Psychiatry · Philadelphia, PA
Hector Colon Rivera
Addiction Psychiatry · Philadelphia, PA
Jaakko Lappalainen
Addiction Psychiatry · Philadelphia, PA
Henry Kranzler
Addiction Psychiatry · Philadelphia, PA
Alexandra McLean
Addiction Psychiatry · Wayne, PA
Arlin Silberman
Addiction Psychiatry · Upland, PA
Related records
Addiction Psychiatry in Pennsylvania
Practitioners in the same specialty and state, ranked by reported value.
All Addiction Psychiatry
Everyone recorded under this specialty, nationwide.
Doctors in Pennsylvania
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.